**AI生物标志物分析公司Nucleai完成1400万美元B+轮融资**
AI驱动的空间生物标志物分析初创公司Nucleai近日宣布，已在B+轮融资中成功筹集1400万美元，这标志着公司在医疗数据分析领域的进一步发展。本轮融资由M Ventures领投，知名投资机构Section 32、Sanofi Ventures、Debiopharm、复星锐正资本、Vertex Ventures Israel和Grove Ventures等现有投资者积极参与。
Nucleai致力于利用人工智能和机器学习技术，对细胞和组织层面的病理图像及空间数据进行深度分析，以期预测疾病的治疗效果和患者预后。这一创新方法有望为精准医疗提供强有力的支持，帮助医生制定更为个性化和有效的治疗方案。
本轮资金的注入将加速Nucleai的研发进程，推动其先进技术在临床实践中的应用，并可能进一步拓展公司的全球市场影响力。Nucleai的首席执行官表示，他们将利用这笔资金提升平台的技术能力，加强与医疗行业的合作，以期在不久的将来为全球的患者和医疗专业人员带来革命性的诊断工具。
Nucleai的成功融资和其在AI生物标志物分析领域的独特定位，不仅体现了投资者对其技术潜力的认可，也预示着AI在医疗健康领域应用的广阔前景。
英语如下：
**AI Biomarker Analysis Company Nucleai Secures $14 Million in B+ Funding Round, Pioneering the Era of Intelligent Pathological Image Analysis**
Keywords: AI bioanalysis, Nucleai funding,病理 image recognition
**AI-driven biomarker analysis firm Nucleai announces $14 million B+ funding round**
Nucleai, a pioneering startup in spatial biomarker analysis powered by AI, has recently disclosed that it has successfully raised $14 million in its B+ funding round, signifying the company’s advancement in the field of medical data analytics. The round was led by M Ventures, with notable investors Section 32, Sanofi Ventures, Debiopharm, Fosun RZ Capital, Vertex Ventures Israel, and Grove Ventures actively participating.
Nucleai focuses on leveraging artificial intelligence and machine learning to perform in-depth analysis of pathological images and spatial data at the cellular and tissue levels, aiming to predict disease treatment response and patient prognosis. This innovative approach has the potential to significantly bolster precision medicine, enabling doctors to devise more personalized and effective treatment strategies.
The fresh injection of funds will accelerate Nucleai’s research and development, facilitate the application of its advanced technology in clinical settings, and potentially expand its global market presence. The company’s CEO stated that they will utilize the capital to enhance the platform’s technological capabilities, deepen collaborations with the healthcare industry, and strive to introduce groundbreaking diagnostic tools to patients and medical professionals worldwide in the near future.
Nucleai’s successful funding and its unique positioning in AI biomarker analysis not only validate investors’ confidence in its technological potential but also foreshadow the vast potential of AI applications in the healthcare sector.
【来源】https://www.calcalistech.com/ctechnews/article/r11brac1a
Views: 1